Under the direction of Dr. Ramón Cacabelos, founder of Euroespes, a specific program is being developed for the development of new products for the treatment of Alzheimer's disease, Parkinson's disease, cerebrovascular disease (migraine, chronic cerebrovascular insufficiency, associated cerebral microinfarcts cardiovascular disease, stroke) and Parkinson's Dementia Complex. The EuroEspes Management announces that two of these products, under a EuroEspes patent, will be launched in 2021 and a third product in 2022.